

## Application for Authority to Prescribe and Supply an Unregistered or (Pharmacy) Extemporaneously-Compounded Schedule 8 Product for Human Therapeutic Use

This form is available online in PDF format (<http://www.health.nsw.gov.au/pharmaceutical>) and should be filled in electronically using a computer. If completing the form by hand, please use BLOCK LETTERS and ensure that all details are legible.

The application form is to be used for:

- unregistered Schedule 8 medicines other than cannabis medicines
- any extemporaneously-compounded Schedule 8 products

Eligible applications are generally processed within 30 business days. Further information in support of the application may be requested.

<b>Section A: Prescriber details</b>			
<b>Prescriber name:</b>			
<i>(first names)</i>		<i>(family name)</i>	
<b>Name of practice:</b>			
<b>Address:</b>			
<b>Suburb/Town:</b>		<b>Postcode:</b>	
<b>Telephone:</b>	<b>Fax:</b>	<b>Email:</b>	
<b>AHPRA registration no:</b>		<b>PBS prescriber no:</b>	
<b>AHPRA specialty/field:</b> <input type="checkbox"/> Pain Medicine <input type="checkbox"/> Addiction Medicine <input type="checkbox"/> Psychiatry <input type="checkbox"/> Rheumatology <input type="checkbox"/> Palliative Medicine <input type="checkbox"/> General Practice <input type="checkbox"/> Paediatrics <input type="checkbox"/> Neurology <input type="checkbox"/> Other specialty, <i>please specify</i>			
<b>Section B: Patient details</b>			
<b>Patient name:</b>			
<i>(first names)</i>		<i>(family name)</i>	
<b>Also known as (if applicable):</b>			
<i>(first names)</i>		<i>(family name)</i>	
<b>Patient residential address:</b>			
<b>Suburb/Town:</b>		<b>Postcode:</b>	
<b>Patient date of birth:</b> ____ ____ ____		<b>Sex:</b> <input type="checkbox"/> Male <input type="checkbox"/> Female	
<b>Do you consider this patient to be drug dependent?</b> <input type="checkbox"/> Y <input type="checkbox"/> N <small>A 'drug dependent person' means a person who has acquired, as a result of repeated administration of a drug of addiction or a prohibited drug within the meaning of the <i>Drug Misuse and Trafficking Act 1985</i>, an overpowering desire for the continued administration of such a drug (section 27 of the <i>Poisons and Therapeutic Goods Act 1966</i>).</small>			
<b>Do you have any of the following concerns?</b>			
<input type="checkbox"/> past/current IV drug use	<input type="checkbox"/> drug seeking	<input type="checkbox"/> unsanctioned dosage escalation	
<input type="checkbox"/> illicit drug use	<input type="checkbox"/> doctor shopping	<input type="checkbox"/> medical dependence	
<input type="checkbox"/> diversion	<input type="checkbox"/> drug misuse	<input type="checkbox"/> lost prescriptions/medication	
<input type="checkbox"/> longer period of use than intended or appropriate			
<input type="checkbox"/> no concerns			

Patient Family Name

<b>Section C: Product details</b>	
<b>Schedule 8 substance/s:</b>	
<b>Is this a proprietary product being imported from overseas?</b>	
<input type="checkbox"/> Y	.....▶ Please attach TGA Special Access Scheme approval
<input type="checkbox"/> N	.....▶ If the product is to be pharmacy compounded the prescriber is advised to seek evidence from the pharmacist that the quality and stability of the formulation is in accordance with the guidelines on compounding medicines published by the Pharmacy Board of Australia.
<b>Form</b> (e.g. capsule, troche, lozenge, injection, cream, gel, mixture, spray):	
<b>Maximum daily dose of the Schedule 8 substance/s:</b>	mg
<b>Quantity/volume to be prescribed (as specified on the prescription):</b>	
<i>Specify the appropriate measurement – gram, mg or mL</i>	
<b>Expected duration of treatment</b> (Specify days, weeks or months, as applicable):	
<b>Section D: Clinical indication and use</b>	
<b>Patient's diagnosis:</b>	
<b>Clinical indication for use:</b>	
<b>Is the patient's condition an ARTG approved indication for use of the Schedule 8 substance(s) contained in the product?</b>	
<i>Note: Therapeutic goods entered in the <a href="#">Australian Register of Therapeutic Goods (ARTG)</a> can be lawfully supplied in Australia. The ARTG holds information on product name and formulation details, as well as sponsor and manufacturer details.</i>	
<input type="checkbox"/> Y	
<input type="checkbox"/> N	.....▶ Please attach a second opinion supporting the treatment from a relevant specialist, if available.
<b>Describe the evidence of efficacy for the product in the treatment of the patient's condition. Provide details of published citations, where available.</b>	

Patient Family Name

**Explain why ARTG products are unsuitable and how this product will form part of the patient's management plan. Include details of pharmacological and non-pharmacological treatments that have previously been trialled.**

**Section E: Attachments**

**Indicate the attachments provided with this application (tick all that apply):**

- TGA Special Access Scheme approval (Section C)
- Second opinion supporting the treatment from a relevant specialist (Section D)

**Section F: Signature**

**I have explained the following to the patient:**

- **the product (as an unregistered medicine) has not been assessed for safety or efficacy by the TGA**
- **the nature of treatment and potential harms, and the patient has consented to the treatment**
- **why their personal health information is collected, how they can access their information, how it may be used, and who it may be disclosed to (see Privacy Statement below)**

**I confirm that the information I have provided in this application is true, accurate and complete to the best of my knowledge.**

Signed: ..... Date: \_\_\_\_ \_

Privacy Statement: The information set out in this form is required by the Ministry of Health for the issuance of an authority to prescribe an unregistered Schedule 8 product as required under the law. The collection, use and disclosure of the information provided will be in accordance with privacy laws. The information collected may be disclosed to health practitioners when necessary to facilitate coordination of treatment and patient safety, and may be disclosed to other State and Commonwealth jurisdictions to facilitate consideration of treatment approvals. Personal information will not be disclosed for any other purpose without prior consent, except where required by law or where otherwise lawfully authorised to do so. The application may not be processed if all information requested on the form is not completed. For further information on privacy visit <http://www.health.nsw.gov.au/patients/privacy>.

*Fax completed form and supporting documentation to the Pharmaceutical Regulatory Unit: 02 9424 5889  
Enquiries: Tel 02 9424 5923 or email [MOH-S8Auth@health.nsw.gov.au](mailto:MOH-S8Auth@health.nsw.gov.au)  
Allow up to 7 business days for the processing of applications.*